

Multiplex Pathogen Identification Panels for Infectious Disease

Humana

Medicaid Medical Coverage Policy

Original Effective Date: 02/04/2025

Effective Date: 01/01/2026

Review Date: 08/05/2025

Policy Number: HUM-2246-002

Line of Business: Medicaid

States: MI

Table of Contents

[Description](#)

[Coverage Limitations](#)

[References](#)

[Appendix](#)

[Coverage Determination](#)

[Coding Information](#)

[Change Summary](#)

Disclaimer

The Medical Coverage Policies are reviewed by the Humana Medicaid Coverage Policy Adoption (MCPA) Forum. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from Humana.

Description

Microbes (eg, bacteria, fungi, parasites, viruses) cause infections in humans. Testing methods for detecting microbes traditionally include detection by cultures or antibody testing. However, since microbes contain genetic material (DNA and RNA), genetic testing methods can be applied to detect pathogens. The genetic material in microbes differs from the genetic material in human cells. Samples used for genetic testing for infectious disease include, but may not be limited to, aspirated fluid around joints, blood, cerebrospinal fluid, sputum, stool and urine. Genetic testing can be used to diagnose infections, identify and type the microbes causing an infection as well as determine if a microbe will respond to a specific treatment.

Genetic testing for infectious disease differs from genetic tests for inherited conditions. Microbes associated with infectious disease contain genetic material, but the genetic material contained within microbes differs from genetic material within human cells. Genetic testing for inherited conditions, also known as germline mutation testing, analyzes an individual's DNA and can identify genetic mutations to determine inherited risk of disease. An individual's germline DNA is constant and identical in all body tissue types. The DNA and RNA of microbes are present only in the tissue sampled, are not representative of an individual's germline DNA and are not inheritable.

The scope of this policy pertains to the outpatient setting only.

Coverage Determination

Nucleic Acid Amplification Tests for Bacterial Vaginitis

Humana members may be eligible under the Plan for **nucleic acid amplification tests (NAATs) for diagnosis of bacterial vaginitis** (eg, BD MAX Vaginal Panel [81514], Aptima BV Assay [81513]) in women with symptoms of vaginitis (eg, abnormal discharge, burning, irritation).²⁹

Respiratory Infection Multiplex Pathogen Identification Panel – Expanded (6 to or More Targets)

Humana members may be eligible under the Plan for **respiratory infection multiplex pathogen identification panel containing 6 or more pathogen targets** (87632, 87633) (eg, BioFire FilmArray Pneumonia (PN) Panel [0528U], BioFire Respiratory Panel 2.1 [0202U], ePlex Respiratory Pathogen (RP) Panel [0115U], ePlex Respiratory Pathogen Panel 2 [0225U], QIAstat-Dx Respiratory SARS-CoV-2 [0223U]) when the following criteria are met:

- Individual presents with signs and symptoms of respiratory infection (eg, cough, dyspnea [short of breath], fever, nasal congestion, runny nose, sore throat, tight chest, wheezing)^{2,4,34}; **AND**
- Results of the test will determine therapeutic management (eg, antibiotic or antiviral treatment)²; **AND**
- Targeted respiratory infection multiplex pathogen identification panel (2-5 pathogen targets [eg, influenza, SARS-CoV-2]) performed prior to expanded panel and is negative²; **AND**
- Individual is immunocompromised and/or considered high-risk for serious complications and includes any of the following²:
 - Currently receiving cancer treatment^{2,4}; **OR**
 - Currently receiving chronic glucocorticoid therapy²; **OR**
 - Diagnosed with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)²; **OR**
 - Diagnosed with inherited disease that affects the immune system (eg, agammaglobulinemia, selective IgA deficiency)²; **OR**
 - Organ transplant recipient^{2,4}

Coverage Limitations

Humana members may **NOT** be eligible under the Plan for **NeXGen Fungal/AFB NGS Assay (0531U)**.

A review of the current medical literature shows that there is **no evidence** to determine that this service is standard medical treatment. There is an absence of current, widely-used treatment guidelines or

acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

Humana members may **NOT** be eligible under the Plan for the following:

- Combination pathogen identification and antibiotic resistance or sensitivity (eg, Respiratory Pathogen with ABR [RPX] [0373U])
- Expanded multiplex vaginitis/vaginosis pathogen panels (Bridge Women’s Health Infectious Disease Detection Test [0330U])^{1,14,20,28,29}
- Metagenomic next-generation sequencing (NGS) including the following:
 - Cell-free DNA (cfDNA) metagenomic NGS (Karius Test [0152U])¹³
 - Johns Hopkins Metagenomic Next-Generation Sequencing Assay for Infectious Disease (0323U)^{19,22}

A review of the current medical literature shows that the **evidence is insufficient** to determine that these services are standard medical treatments. There is an absence of current, widely-used treatment guidelines or acceptable clinical literature examining benefit and long-term clinical outcomes establishing the value of these services in clinical management.

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis	

Multiplex Pathogen Identification Panels for Infectious Disease

81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported	
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets	
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets	
0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens	
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	

Multiplex Pathogen Identification Panels for Infectious Disease

0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	
0323U	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi	
0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab	
0373U	Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen	
0528U	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial-resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria	New Code Effective Date 01/01/2025
0531U	Infectious disease (acid-fast bacteria and invasive fungi), DNA (673 organisms), next-generation sequencing, plasma	New Code Effective Date 04/01/2025
CPT® Category III Code(s)	Description	Comments
No code(s) identified		
HCPCS Code(s)	Description	Comments
No code(s) identified		

References

- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin. Vaginitis in nonpregnant patients. <https://acog.org>. Published May 2006. Updated 2022.
- Association for Diagnostics & Laboratory Medicine (ADLM). ADLM guidance document on laboratory diagnosis of respiratory viruses. <https://myadlm.org>. Published May 2, 2024.

3. Centers for Disease Control (CDC) and Prevention. Sexually transmitted infections treatment guidelines, 2021. <https://cdc.gov>. Published July 23, 2021.
4. Charlton CL, Babady E, Ginocchio CC, et al. Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections. *Clin Microbiol Rev.* 2018;32(1):e00042-18.
5. ClinicalKey. Chapin K. Laboratory diagnosis of infectious diseases. In Wing EJ, Schiffman FJ. *Cecil Essentials of Medicine*. 10th ed. Elsevier; 2022:842-847. <https://clinicalkey.com>.
6. ClinicalKey. Clinical Overview. Bacterial vaginosis. <https://clinicalkey.com>. Updated May 12, 2022.
7. ClinicalKey. Clinical Overview. Trichomoniasis. <https://clinicalkey.com>. Updated April 26, 2022.
8. ClinicalKey. Clinical Overview. Vulvovaginitis - approach to the patient. <https://clinicalkey.com>. Updated January 31, 2025.
9. Flurin L, Fisher CR, Wolf MJ, Pritt BS, DeSimone DC, Patel R. Comparison of blood-based shotgun and targeted metagenomic sequencing for microbiological diagnosis of infective endocarditis. *Open Forum Infect Dis.* 2023;10(12):ofad546.
10. Gao D, Hu Y, Jiang X, Pu H, Guo Z, Zhang Y. Applying the pathogen-targeted next-generation sequencing method to pathogen identification in cerebrospinal fluid. *Ann Transl Med.* 2021;9(22):1675.
11. Hayes, Inc. Clinical Utility Evaluation. Next-generation sequencing (NGS) for identification of microbial pathogens in infections. <https://evidence.hayesinc.com>. Published February 23, 2017. Updated April 6, 2021.
12. Hayes, Inc. Molecular Test Assessment. FilmArray Respiratory Panel 2 (BioFire Diagnostics LLC). <https://evidence.hayesinc.com>. Published May 21, 2020. Updated March 31, 2023.
13. Hayes, Inc. Molecular Test Assessment. Karius Test (Karius Inc.) to diagnose infections in immunocompromised or vulnerable hospitalized patients. <https://evidence.hayesinc.com>. Published August 10, 2022. Updated September 20, 2024.
14. Hayes, Inc. Molecular Test Assessment. Multitarget panels for identification of vaginal pathogens. <https://evidence.hayesinc.com>. Published June 16, 2023. Updated June 5, 2024.
15. Hayes, Inc. Precision Medicine Research Brief. Multi-target panels for identification of respiratory pathogens. <https://evidence.hayesinc.com>. Published October 18, 2022.
16. Hogan CA, Yan S, Garner OB, et al. Clinical impact of metagenomic next-generation sequencing of plasma cell-free DNA for the diagnosis of infectious diseases: a multicenter retrospective cohort study. *Clin Infect Dis.* 2021;72(2):239-245.

17. Infectious Diseases Society of America (IDSA). Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). <https://idsociety.org>. Published March 5, 2024.
18. Rodino KG, Toledano M, Norgan AP, et al. Retrospective review of clinical utility of shotgun metagenomic sequencing testing of cerebrospinal fluid from a U.S. tertiary care medical center. *J Clin Microbiol*. 2020;58(12):e01729-20.
19. UpToDate, Inc. Approach to the patient with chronic meningitis. <https://uptodate.com>. Updated December 2024.
20. UpToDate, Inc. Bacterial vaginosis: clinical manifestations and diagnosis. <https://uptodate.com>. Updated February 26, 2025.
21. UpToDate, Inc. Candida vulvovaginitis: clinical manifestations and diagnosis. <https://uptodate.com>. Updated February 2025.
22. UpToDate, Inc. Health care-associated meningitis and ventriculitis in adults: clinical features and diagnosis. <https://uptodate.com>. Updated December 2024.
23. UpToDate, Inc. Hepatitis C infection in kidney transplant candidates and recipients. <https://uptodate.com>. Updated February 2025.
24. UpToDate, Inc. Human metapneumovirus infections. <https://uptodate.com>. Updated February 2025.
25. UpToDate, Inc. Molecular diagnosis of central nervous system infections. <https://uptodate.com>. Updated December 2024.
26. UpToDate, Inc. Mycoplasma pneumoniae infection in adults. <https://uptodate.com>. Updated February 2025.
27. UpToDate, Inc. Pertussis infection in infants and children: clinical features and diagnosis. <https://uptodate.com>. Updated February 2025.
28. UpToDate, Inc. Trichomoniasis: clinical manifestations and diagnosis. <https://uptodate.com>. Updated February 2025.
29. UpToDate, Inc. Vaginitis in adults: initial evaluation. <https://uptodate.com>. Updated February 2025.
30. US Centers for Disease Control & Prevention (CDC). Rapid diagnostic tests for infectious diseases: CDC Yellow Book 2024. <https://cdc.gov>. Updated May 1, 2023.
31. US Food & Drug Administration (FDA). 501k approval summary: BIOFIRE FILMARRAY Pneumonia Panel (BIOFIRE Pneumonia Panel); BIOFIRE FILMARRAY Pneumonia Panel Plus (BIOFIRE Pneumonia Panel Plus). <https://fda.gov>. Published November 6, 2024.

32. US Food & Drug Administration (FDA). 501k approval summary: ePlex Respiratory Pathogen Panel. <https://fda.gov>. Published June 9, 2017.
33. US Food & Drug Administration (FDA). De novo decision summary: BD MAX Vaginal Panel, BD MAX Instrument. <https://fda.gov>. Published October 28, 2016.
34. US Food & Drug Administration (FDA). De novo decision summary: BioFire Respiratory Panel 2.1 (RP2.1). <https://fda.gov>. Published March 17, 2021.
35. Wilson MR, O'Donovan BD, Gelfand JM, et al. Chronic meningitis investigated via metagenomic next-generation sequencing. *JAMA Neurol.* 2018;75(8):947-955.
36. Wilson MR, Sample HA, Zorn KC, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. *N Engl J Med.* 2019;380(24):2327-2340.
37. Yan L, Sun W, Lu Z, Fan L. Metagenomic next-generation sequencing (mNGS) in cerebrospinal fluid for rapid diagnosis of tuberculosis meningitis in HIV-negative population. *Int J Infect Dis.* 2020;96:270-275.

Change Summary

02/04/2025 New Policy.

04/01/2025 Update, Coverage Change. Provider Claims Codes Update.

08/05/2025 Update, Coverage Change. Provider Claims Codes Update.